6 completed, 1 terminated, 1 unknown. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 6, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Recurrent Glioblastoma Multiforme: new trials by email Literature Review of Recurrent Glioblastoma Multiforme trials Research Report on Recurrent Glioblastoma Multiforme
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) Berubicin Hydrochloride - Recurrent Glioblastoma Multiforme | Phase 1 / Phase 2 | Terminated | WPD Pharmaceuticals Sp. z o.o. | 5 | 2022-12-07 | 2024-06-06 |
| The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma SNC-109 CAR-T Cells - Recurrent Glioblastoma Multiforme | Phase 1 | Unknown | Shanghai Simnova Biotechnology Co.,Ltd. | 16 | 2022-06-24 | 2024-02-23 |
| A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Radiation Therapy, AZD1390 - Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme | Phase 1 | Completed | AstraZeneca | 159 | 2018-04-02 | 2026-10-15 |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme buparlisib, carboplatin, lomustine - Recurrent Glioblastoma Multiforme | Phase 1 | Completed | Novartis Pharmaceuticals | 35 | 2014-02-28 | 2020-12-09 |
| Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma M032 (NSC 733972) - Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme | Phase 1 | Completed | University of Alabama at Birmingham | 29 | 2013-11-25 | 2026-11-04 |
| Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors LDE225, BKM120 - Dose Escalation, Safety | Phase 1 | Completed | Novartis Pharmaceuticals | 120 | 2012-07-01 | 2020-12-19 |
| Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors AutoLITT system - Brain Tumor, Brain Tumor, Recurrent | Phase 1 | Completed | Monteris Medical | 10 | 2008-08-01 | 2021-08-24 |
| Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme 131-I-chTNT-1/B MAB - Recurrent Glioblastoma Multiforme | Phase 1 | Completed | Peregrine Pharmaceuticals | 12 | 2006-11-01 | 2011-08-05 |
Glioblastoma (8) · Brain Neoplasms (4) · Astrocytoma (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Glioma (1) · Gliosarcoma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Inhibition, Psychological (1) · Meningeal Neoplasms (1) · Stomach Neoplasms (1) · Virus Diseases (1)
Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Germ Cell and Embryonal (8) · Neoplasms, Glandular and Epithelial (8) · Neoplasms, Nerve Tissue (8) · Neoplasms, Neuroepithelial (8) · Neuroectodermal Tumors (8) · Astrocytoma (7) · Glioma (7) · Neoplasms by Site (5) · Brain Diseases (4) · Central Nervous System Diseases (4) · Central Nervous System Neoplasms (4) · Nervous System Diseases (4) · Nervous System Neoplasms (4)
NVP-BKM120 (2) · 131I-chimeric TNT-1-B monoclonal antibody (1) · AZD1390 (1) · Carboplatin (1) · Lomustine (1) · Radiotherapy (1) · sonidegib (1)
Novartis Pharmaceuticals (2) · AstraZeneca (1) · Monteris Medical (1) · Peregrine Pharmaceuticals (1) · Shanghai Simnova Biotechnology Co.,Ltd. (1) · University of Alabama at Birmingham (1) · WPD Pharmaceuticals Sp. z o.o. (1)
United States (6) · Australia (2) · Belgium (2) · Canada (2) · Spain (2) · United Kingdom (2) · China (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Poland (1)
Andrew E Sloan, MD, FACS (1) · Andrew Sloan, MD (1) · Anthony Chalmers (1) · Brandon Imber (1) · Deborah Forst (1) · Gene Barnett, MD (1) · James M. Markert, MD (1) · Jan Drappatz (1) · Kazuhiko Mishima (1) · Kenneth M Spicer, MD PhD (1) · Kevin D Judy, MD (1) · Louise Murray (1) · Mariza Daras (1)
2017 (1), R01CA217179 (1)